Why choose Gilead?
At Gilead, we strive to transform and simplify care for people with life-threatening diseases around the world.
Who leads the fight against cancer in Gilead?
Daejin Abidoye and Oriana Wiklund lead with passion and determination in the fight against cancer. Watch them in discussion to learn about their careers and Gilead’s innovative work in oncology.
What is the Gilead compass initiative?
Gilead launches the COMPASS Initiative™ to help address the HIV/AIDS epidemic in the Southern United States. Gilead COMPASS Initiative. Supporting Elimination Efforts. With the emergence of new therapies that have transformed chronic HCV treatment, it is now possible to eliminate the disease in certain populations.
What is Gilead focused on?
Who does Gilead collaborate with?
What is Gilead exploring?
About this website
Remdesivir | Gilead
On April 25, 2022, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for Veklury ® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including …
Gilead Sciences Statement on The World Health Organization’s Updated …
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines. Foster City, Calif., November 19, 2020 –Veklury® (remdesivir) is recognized as a standard of care for the treatment of hospitalized patients with COVID-19 in guidelines from numerous credible national organizations, including the US National Institutes of Health and …
Gilead CEO: Oral version of Covid drug Remdesivir in early testing – CNBC
Gilead CEO Daniel O’Day sits down with CNBC’s Meg Tirrell and the ‘Squawk on the Street’ team to discuss the company’s Covid-19 antiviral, Remdesivir.
Remdesivir | COVID-19 Treatment Guidelines
Learn more about studies investigating remdesivir and how the drug may benefit people with severe COVID-19 disease.
Gilead’s Veklury shows ‘no antiviral effects,’ small WHO study says as …
Veklury has become routine treatment for severe COVID-19 patients in the U.S., spurring significant sales for Gilead Sciences.
What is Gilead focused on?
Gilead is focused on deploying our resources and decades of antiviral expertise to help patients and communities fighting the COVID-19 pandemic.
Who does Gilead collaborate with?
Gilead continues to collaborate with global health authorities, government agencies, healthcare systems, academic institutions, non-profit organizations, and individual researchers and clinicians to share and update information and to bring the full weight of our science to help end this pandemic.
What is Gilead exploring?
Gilead is also exploring novel oral antivirals for the treatment of non-hospitalized COVID-19 patients.
Información sobre la empresa Gilead
La emprea Gilead Sciencies se ha posicionado en el sector de actividad farmacéutico y es una referencia en temas de desarrollo, producción y venta de productos terapéuticos. Entre su mercado propone principalmente la venta de medicamentos, en especial aquellos que actúan en contra del VIH.
Datos económicos y financieros de Gilead
El precio de las acciones Gilead Sciences cotiza actualmente en el Nasdaq Select Market de Estados Unidos e integra el cálculo del índice bursátil Nasdaq 100.
Acciones Gilead: Recomendaciones para operar
La cotización de las acciones Gilead evoluciona de acuerdo a factores que se repiten, lo cual nos da un margen de previsión respecto a las futuras tendencias. Por consiguiente, nuestra recomendación es sencillamente analizar los diferentes indicadores, tales como:
What is Gilead focused on?
Gilead is focused on deploying our resources and decades of antiviral expertise to help patients and communities fighting the COVID-19 pandemic.
Who does Gilead collaborate with?
Gilead continues to collaborate with global health authorities, government agencies, healthcare systems, academic institutions, non-profit organizations, and individual researchers and clinicians to share and update information and to bring the full weight of our science to help end this pandemic.
What is Gilead exploring?
Gilead is also exploring novel oral antivirals for the treatment of non-hospitalized COVID-19 patients.
